查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2012624

腦腫瘤治療市場：2026-2032年全球市場預測（按產品類型、治療方法、腫瘤類型、通路和最終用戶分類）

Brain Tumor Therapeutics Market by Product Type, Therapeutic Approach, Tumor Type, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，腦腫瘤治療市場價值將達到 35.6 億美元，到 2026 年將成長至 38.7 億美元，到 2032 年將達到 69.9 億美元，複合年成長率為 10.10%。

主要市場統計數據
基準年 2025 35.6億美元
預計年份：2026年 38.7億美元
預測年份 2032 69.9億美元
複合年成長率 (%) 10.10%

對於決策者而言，我們整合臨床創新、護理路徑和商業化的優勢，以建構現代化的腦腫瘤治療格局。

腦腫瘤治療處於快速科學創新與持續臨床複雜性交彙的階段，需要一種整合技術、臨床實踐和商業策略的整體商業觀點。分子診斷和精準醫療的最新進展正在改變患者的治療路徑，拓寬可用的治療方法範圍，同時也提升了多學科協作的重要性。同時，影像學和外科技術的創新正在改變手術全期決策，並為醫療設備和服務供應商創造新的機遇，使其能夠創造可衡量的價值。

精準診斷、適應性證據產生和價值驅動型護理模式如何重塑治療方法的開發和商業性化應用。

腦腫瘤治療領域正經歷著變革性的轉變，這些轉變正在重新定義臨床決策和商業性優先事項。精準腫瘤學的進步，例如分子分型和標靶免疫療法，正在將異質性疾病類別轉化為更具實用性的治療群體，從而影響臨床試驗設計、監管策略和市場准入順序。除了藥物研發的進步之外，影像和放射技術也在不斷發展，提高了診斷的準確性並減少了繼發性損傷，這迫使臨床團隊重新評估治療順序和聯合治療策略。

本研究評估了近期關稅趨勢如何改變了治療藥物和醫療設備。

貿易政策和關稅趨勢會對所有治療領域的製造商和經銷商的原料成本和供應鏈產生重大影響。 2025年，美國關稅的變化將對進口醫療設備和某些醫藥原料產生累積影響，迫使製造商重新評估其籌資策略和成本結構。對於醫療設備製造商而言，依賴全球化供應鏈的組件，例如成像感測器和放射治療系統零件，正面臨原料成本飆升的困境，這導致他們不得不重新評估與醫院系統和經銷商商的採購談判。

本分析檢視了醫療設備和藥品的需求因素以及臨床路徑，以確定不同的引進模式和關鍵的商業化策略。

關鍵的市場區隔洞察揭示了臨床需求和商業性機會在產品類型、治療方法、腫瘤類型、終端用戶和分銷管道等方面的交匯點。依產品類型分析，市場分為醫療設備和藥品兩大類，其中醫療設備又包括影像設備、放射治療設備和手術器材。這種細分突顯了不同引進週期、資本投資情況以及醫療服務提供者的服務模式需求。治療方法進一步細分了市場需求，涵蓋化療、免疫療法、放射線治療和外科手術。化療包括烷化劑、抗代謝藥物和植物生物鹼；免疫療法包括CAR-T療法、查核點抑制劑和疫苗；放射線治療包括近距離放射、體外放射治療和立體定位放射放射線手術。另一方面，外科手術方法涵蓋從開顱手術到立體定位手術，每種方法都有其獨特的臨床工作流程和實證醫學需求。

此流程旨在明確區域法規和支付方多樣性，並最佳化證據生成、市場進入順序和區域商業化策略，以實現全球擴張。

區域趨勢決定了監管、報銷和臨床導入環境的差異，因此需要製定本地化的打入市場策略。在美洲，先進的學術機構和綜合醫療保健系統往往推動高成本療法和複雜醫療設備的早期應用，而私人保險公司和打包支付模式則影響著醫療服務的取得和報銷途徑。在歐洲、中東和非洲，監管的多樣性和報銷標準的差異，以及集中核准系統和分散式醫療技術評估並存的現狀，使得靈活的循證數據和區域性經濟模式成為必要。亞太地區的醫療現代化過程呈現多樣化的發展路徑。在一些市場，醫院的快速擴張和對腫瘤中心的投資催生了對高性能醫療設備和新型療法的巨大需求，而在其他市場，成本控制和本地化生產夥伴關係至關重要。

創新者、醫療設備製造商和經銷商如何透過整合產品和服務策略來重新定義競爭優勢和夥伴關係模式。

腦腫瘤治療生態系統中的主要企業在互補領域開展業務，包括創新藥物研發商、醫療設備製造商、服務供應商和專業經銷商，他們各自為複雜的價值鏈做出貢獻。製藥創新者正日益將分子標靶藥物和免疫療法與伴隨診斷相結合，而基於生物標記的患者選擇在臨床和商業性成功中發揮越來越重要的作用。醫療設備製造商則透過整合成像、導航和藥物輸送的整合解決方案來脫穎而出，從而簡化手術流程並改善臨床療效。

為了加快招募速度，經營團隊優先考慮整合證據產生、供應彈性和靈活的商業化。

產業領導者應優先考慮一系列切實可行的舉措，使科學差異化與現實的商業性可行性和支付方的預期相契合。首先，投資於有針對性的證據生成，將臨床終點與衛生經濟效益連結起來，使支付者和醫療保健系統不僅能夠評估短期療效，還能評估長期價值。其次，透過採購多元化、確保關鍵零件的冗餘以及將關稅和貿易敏感性分析納入定價模式，最佳化供應鏈韌性，以保障獲利能力和醫療保健服務的連續性。第三，開發能夠反映終端用戶多樣性的靈活商業模式。醫院、門診手術中心和專科診所各自需要不同的部署、資金籌措和服務合約。

我們結合臨床、商業和政策知識，採用透明的混合方法（包括專家訪談和比較案例分析），確保提供可操作的見解。

本分析的調查方法結合了系統性的文獻綜述、對各領域專家的定性檢驗以及對二手資料來源的三角驗證，以確保研究結果的穩健性和有效性。訪談對象包括臨床醫生、醫院採購經理、醫療設備工程師、保險公司和商業部門主管，旨在收集不同領域對臨床效用、採購偏好和市場進入風險的觀點。二級資訊來源，包括同行評審的臨床文獻、監管文件、指南更新和公共公告，均基於檢驗的證據和當前的實踐模式，為研究結果提供了支持。

找到能夠整合臨床創新、商業性嚴謹性和區域差異的策略槓桿，將治療進步轉化為持久影響。

總之，腦腫瘤治療領域的特點是科學進步日新月異、診療路徑不斷演變以及商業性環境複雜多變，所有這些因素共同要求在實證醫學、供應鏈設計和市場進入方面採取整合策略。精準診斷和新型免疫療法提高了臨床鑑別診斷的標準，而影像學、放射療法和外科手術技術的進步正在重塑治療模式。同時，關稅和貿易的波動暴露了供應鏈的脆弱性，需要積極主動的管理來維持醫療資源的可近性和財務績效。監管和報銷機制的區域差異進一步凸顯了製定區域性策略和夥伴關係關係的必要性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：腦腫瘤治療市場：依產品類型分類

  • 醫療設備
    • 醫療影像設備
    • 放射治療設備
    • 手術器械
  • 製藥

第9章：腦腫瘤藥物市場（依治療方法分類）

  • 化療
    • 烷化劑
    • 抗代謝物
    • 植物生物鹼
  • 免疫療法
    • CAR T
    • 查核點抑制劑
    • 疫苗
  • 放射線治療
    • 近距離放射治療
    • 遠端輻射
    • 立體定位放射放射線手術
  • 外科手術
    • 開顱手術
    • 立體定位手術

第10章：依腫瘤類型分類的腦腫瘤治療市場

  • 星狀細胞瘤
  • 膠質母細胞瘤
  • 腦膜瘤

第11章：腦腫瘤治療市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第12章：腦腫瘤治療市場：依最終用戶分類

  • 門診手術中心
  • 醫院
  • 專科診所

第13章：腦腫瘤治療市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章：腦腫瘤治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 腦腫瘤治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國腦腫瘤治療市場

第17章：中國腦腫瘤治療市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca plc
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Celldex Therapeutics, Inc.
  • CNS Pharmaceuticals, Inc.
  • Daiichi Sankyo Co., Ltd.
  • Eisai Co., Ltd.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Kintara Therapeutics, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Novocure Ltd.
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-4342CA326550

The Brain Tumor Therapeutics Market was valued at USD 3.56 billion in 2025 and is projected to grow to USD 3.87 billion in 2026, with a CAGR of 10.10%, reaching USD 6.99 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.56 billion
Estimated Year [2026] USD 3.87 billion
Forecast Year [2032] USD 6.99 billion
CAGR (%) 10.10%

Framing the contemporary brain tumor therapeutic environment by integrating clinical innovation, care pathways, and commercialization levers for decision-makers

Brain tumor therapeutics sit at the intersection of rapid scientific innovation and enduring clinical complexity, requiring an executive lens that integrates technology, clinical practice, and commercial strategy. Recent advances in molecular diagnostics and precision therapeutics have altered patient pathways, expanding the range of interventions available while also increasing the importance of coordinated care across multidisciplinary teams. At the same time, procedural innovations in imaging and surgical techniques have changed perioperative decision making, creating new opportunities for device and service providers to add demonstrable value.

This introduction positions the report as a focused synthesis of clinical, regulatory, and commercial dynamics shaping therapeutic choices for primary brain tumors. It outlines the prevailing therapeutic approaches, the role of complementary devices, and how end users such as hospitals, specialty clinics, and ambulatory surgical centers are adapting care pathways. Throughout, emphasis is placed on evidence-based adoption drivers, reimbursement and access considerations, and the strategic implications for companies developing devices or pharmacologic therapies. The aim is to equip decision-makers with a concise framing of the problem set, the levers that matter in commercialization, and the domains where additional investment or collaboration can yield measurable clinical and economic returns.

How precision diagnostics, adaptive evidence generation, and value-focused care models are reshaping therapeutic development and commercial execution

The landscape for brain tumor therapeutics is undergoing transformative shifts that are redefining clinical decision-making and commercial priorities. Precision oncology advances, such as molecular subtyping and targeted immunotherapies, have converted heterogeneous disease categories into more actionable treatment cohorts, thereby influencing trial design, regulatory strategy, and market entry sequencing. Parallel to pharmacologic progress, imaging and radiation technologies have evolved to provide greater precision and reduced collateral damage, prompting clinical teams to reassess treatment sequencing and combination strategies.

Concurrently, the convergence of digital health, real-world evidence, and adaptive clinical trial frameworks has accelerated iterative learning, shortening the time between proof-of-concept and broader clinical adoption. Payers and health systems are increasingly focused on value-based metrics, pushing manufacturers to demonstrate not only efficacy but also longitudinal patient outcomes and cost-effectiveness. As a result, organizations that can align scientific differentiation with pragmatic deployment pathways-such as optimized distribution channels and hospital integration models-will capture disproportionate clinical and commercial upside. These shifts compel manufacturers and providers to rethink partnerships, evidence generation, and market access pathways in order to remain competitive.

Assessing how recent tariff developments have altered supply chain resilience, procurement dynamics, and commercial cost structures in therapeutics and devices

Trade policy and tariff dynamics can introduce material cost and supply chain considerations for manufacturers and distributors across therapeutic modalities. In 2025, tariff changes in the United States have had a cumulative effect on imported devices and certain pharmaceutical inputs, prompting manufacturers to reassess sourcing strategies and cost structures. For device makers, components that rely on globalized supply chains, including imaging sensors or radiation delivery system parts, experienced input-cost inflation that translated to revised procurement discussions with hospital systems and distributors.

Pharmaceutical manufacturers faced indirect cost pressure where APIs and specialty packaging were sourced internationally, requiring contract renegotiations and, in some instances, partial reshoring or diversification of suppliers. These adjustments increase the importance of supply chain transparency and contractual flexibility with end users. Providers and payers responded by seeking stronger total-cost-of-care evidence and longer-term warranties or service commitments to mitigate variability. Moving forward, stakeholders that proactively model tariff-related expenses into pricing, managed procurement, and clinical value propositions will be better positioned to sustain margins while preserving access and adoption.

Dissecting demand drivers across devices versus pharmaceuticals and clinical pathways to reveal differentiated adoption patterns and commercialization levers

Key segmentation insights reveal where clinical demand and commercial opportunity intersect across product type, therapeutic approach, tumor type, end user, and distribution channels. When analyzed by product type, the market divides into devices and pharmaceutical offerings, with devices themselves comprising imaging equipment, radiation equipment, and surgical instruments; this division highlights different adoption cycles, capital expenditure profiles, and service model requirements for providers. Therapeutic approach further stratifies demand across chemotherapy, immunotherapy, radiotherapy, and surgery; chemotherapy includes alkylating agents, antimetabolites, and plant alkaloids, while immunotherapy encompasses CAR T therapies, checkpoint inhibitors, and vaccines, and radiotherapy spans brachytherapy, external beam radiotherapy, and stereotactic radiosurgery, whereas surgical approaches range from craniotomy to stereotactic surgery, each pathway implicating distinct clinical workflows and evidence needs.

Tumor type segmentation-astrocytoma, glioblastoma, and meningioma-illustrates heterogeneous clinical outcomes and treatment intensity, which in turn affect product selection and service utilization. End users such as ambulatory surgical centers, hospitals, and specialty clinics differ in their capital budgets, case-mix, and referral networks, shaping procurement timelines and commercial engagement strategies. Distribution channels including hospital pharmacies, online pharmacies, and retail pharmacies influence patient access, adherence support, and channel economics. Taken together, these segmentations underline that tailoring clinical evidence, pricing models, and post-market services to the specific combination of product, therapy, tumor type, and care setting is essential to accelerate adoption and create defensible commercial positioning.

Unpacking regional regulatory and payer heterogeneity to tailor evidence generation, market entry sequencing, and local commercialization tactics for global reach

Regional dynamics create distinct regulatory, reimbursement, and clinical adoption environments that require localized go-to-market strategies. In the Americas, advanced academic centers and integrated health systems often drive early adoption of high-cost therapeutics and complex devices, while private payers and bundled payment models shape access and reimbursement pathways. Europe, the Middle East & Africa encompasses regulatory heterogeneity and varying reimbursement thresholds, where centralized approvals coexist with decentralized health technology assessments, necessitating flexible evidence dossiers and region-specific economic models. Asia-Pacific presents diverse healthcare modernization trajectories; in some markets rapid hospital expansion and investment in oncology centers create significant demand for high-capability devices and novel therapeutics, whereas other markets emphasize cost containment and local manufacturing partnerships.

These regional contrasts affect clinical trial site selection, timing of market entry, and the design of patient access programs. Manufacturers must therefore calibrate regulatory strategies, local evidence generation, and distribution partnerships to align with regional payer expectations and provider capabilities. Moreover, engagement with key opinion leaders and local clinical networks is essential to translate global evidence into locally relevant practice change and to expedite reimbursement discussions in each jurisdiction.

How integrated product and service strategies among innovators, device makers, and distributors are redefining competitive advantage and partnership models

Key companies in the brain tumor therapeutics ecosystem operate across complementary domains-innovative drug developers, device manufacturers, service providers, and specialized distributors-each contributing to a complex value chain. Pharmaceutical innovators are increasingly pairing molecularly targeted agents and immunotherapies with companion diagnostics, elevating the role of biomarker-driven patient selection in clinical and commercial success. Device manufacturers are differentiating through integrated solutions that combine imaging, navigation, and therapeutic delivery to streamline operative workflows and improve clinical outcomes.

Service providers and contract research organizations are expanding offerings to support adaptive trial designs, real-world evidence platforms, and health economic modeling, enabling sponsors to substantiate value propositions more rapidly. Distributors and specialty pharmacies are enhancing patient support programs and specialty logistics to address the needs of high-acuity populations. Across the ecosystem, strategic collaborations-whether co-development, licensing, or integrated service agreements-have become a preferred vehicle to de-risk innovation and accelerate time-to-clinic or time-to-market. Organizations that can demonstrate integrated solutions, scalable support models, and strong clinical evidence will lead in both clinical adoption and long-term commercial sustainability.

Prioritized strategic moves for executives to synchronize evidence generation, supply resilience, and flexible commercialization to accelerate adoption

Industry leaders should prioritize a set of actionable initiatives that align scientific differentiation with pragmatic commercial execution and payer expectations. First, invest in targeted evidence generation that pairs clinical endpoints with health economic outcomes, enabling payers and health systems to assess long-term value alongside short-term efficacy. Second, optimize supply chain resilience by diversifying sourcing, building redundancy for critical components, and embedding tariff and trade sensitivity analyses into pricing models to protect margins and continuity of care. Third, develop flexible commercial models that reflect end-user variability; hospitals, ambulatory surgical centers, and specialty clinics require different acquisition, financing, and service arrangements.

Additionally, engage early with regional regulatory and reimbursement stakeholders to ensure local evidence requirements are met, and consider adaptive trial designs or pragmatic studies to accelerate real-world adoption. Form strategic alliances that integrate devices and therapeutics with digital tools and patient support services to create bundled value propositions. Finally, prioritize clinician and patient education programs that clarify treatment sequencing, combination therapy rationale, and outcome expectations, thereby smoothing the pathway from regulatory approval to standard-of-care integration. Collectively, these actions will reduce barriers to adoption and enhance commercial resilience.

A transparent mixed-methods approach combining clinical, commercial, and policy intelligence with expert interviews and comparative case analyses to ensure actionable insights

The research methodology underpinning this analysis combines systematic literature review, primary qualitative interviews with subject matter experts, and triangulation of secondary data sources to ensure robustness and relevance. Primary interviews included clinicians, hospital procurement leaders, device engineers, payers, and commercial executives to capture cross-functional perspectives on clinical utility, procurement preferences, and market access contingencies. Secondary sources encompassed peer-reviewed clinical literature, regulatory filings, guideline updates, and public policy announcements to ground the findings in verifiable evidence and current practice patterns.

Data synthesis employed thematic analysis to identify recurring adoption drivers, barriers, and regional variances, while comparative case studies highlighted successful commercialization and partnership archetypes. Where appropriate, sensitivity checks were performed to validate assumptions around supply chain dynamics and provider purchasing behaviors. The methodology emphasizes transparency in source attribution and analytical assumptions and was designed to produce actionable insights that are reliable for strategic planning, partnership evaluation, and evidence generation prioritization.

Synthesizing clinical innovation, commercial rigor, and regional nuance to identify the strategic levers that convert therapeutic advances into durable impact

In conclusion, the brain tumor therapeutics arena is characterized by rapid scientific progress, evolving care pathways, and complex commercial dynamics that together demand integrated strategies across evidence generation, supply chain design, and market access. Precision diagnostics and novel immunotherapies have raised the bar for clinical differentiation, while advances in imaging, radiation delivery, and surgical technique are reshaping practice patterns. At the same time, tariff and trade shifts have exposed supply chain vulnerabilities that require proactive management to preserve access and fiscal performance. Regional heterogeneity in regulation and reimbursement further underscores the need for localized strategies and partnerships.

Taken together, organizations that can align robust clinical evidence with pragmatic commercial models, resilient procurement practices, and targeted regional engagement will be best positioned to convert innovation into sustained clinical and commercial impact. The path forward emphasizes collaboration across industry, clinical, and payer stakeholders, and a disciplined approach to evidence and value demonstration that meets the needs of providers and patients alike.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Brain Tumor Therapeutics Market, by Product Type

  • 8.1. Devices
    • 8.1.1. Imaging Equipment
    • 8.1.2. Radiation Equipment
    • 8.1.3. Surgical Instruments
  • 8.2. Pharmaceutical

9. Brain Tumor Therapeutics Market, by Therapeutic Approach

  • 9.1. Chemotherapy
    • 9.1.1. Alkylating Agents
    • 9.1.2. Antimetabolites
    • 9.1.3. Plant Alkaloids
  • 9.2. Immunotherapy
    • 9.2.1. CAR T
    • 9.2.2. Checkpoint Inhibitors
    • 9.2.3. Vaccines
  • 9.3. Radiotherapy
    • 9.3.1. Brachytherapy
    • 9.3.2. External Beam Radiotherapy
    • 9.3.3. Stereotactic Radiosurgery
  • 9.4. Surgery
    • 9.4.1. Craniotomy
    • 9.4.2. Stereotactic Surgery

10. Brain Tumor Therapeutics Market, by Tumor Type

  • 10.1. Astrocytoma
  • 10.2. Glioblastoma
  • 10.3. Meningioma

11. Brain Tumor Therapeutics Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
  • 11.2. Online Pharmacies
  • 11.3. Retail Pharmacies

12. Brain Tumor Therapeutics Market, by End User

  • 12.1. Ambulatory Surgical Centers
  • 12.2. Hospitals
  • 12.3. Specialty Clinics

13. Brain Tumor Therapeutics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Brain Tumor Therapeutics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Brain Tumor Therapeutics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Brain Tumor Therapeutics Market

17. China Brain Tumor Therapeutics Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AbbVie Inc.
  • 18.6. Amgen Inc.
  • 18.7. AstraZeneca plc
  • 18.8. Bayer AG
  • 18.9. Bristol-Myers Squibb Company
  • 18.10. Celldex Therapeutics, Inc.
  • 18.11. CNS Pharmaceuticals, Inc.
  • 18.12. Daiichi Sankyo Co., Ltd.
  • 18.13. Eisai Co., Ltd.
  • 18.14. F. Hoffmann-La Roche Ltd.
  • 18.15. GlaxoSmithKline plc
  • 18.16. Kintara Therapeutics, Inc.
  • 18.17. Merck & Co., Inc.
  • 18.18. Novartis AG
  • 18.19. Novocure Ltd.
  • 18.20. Pfizer Inc.
  • 18.21. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES BRAIN TUMOR THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA BRAIN TUMOR THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMAGING EQUIPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMAGING EQUIPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMAGING EQUIPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIATION EQUIPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIATION EQUIPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIATION EQUIPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGICAL INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGICAL INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGICAL INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PHARMACEUTICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PHARMACEUTICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PHARMACEUTICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ALKYLATING AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ALKYLATING AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ANTIMETABOLITES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ANTIMETABOLITES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ANTIMETABOLITES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PLANT ALKALOIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PLANT ALKALOIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PLANT ALKALOIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CAR T, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CAR T, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CAR T, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY BRACHYTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY BRACHYTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY BRACHYTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY EXTERNAL BEAM RADIOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY EXTERNAL BEAM RADIOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY EXTERNAL BEAM RADIOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY STEREOTACTIC RADIOSURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY STEREOTACTIC RADIOSURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY STEREOTACTIC RADIOSURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CRANIOTOMY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CRANIOTOMY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CRANIOTOMY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY STEREOTACTIC SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY STEREOTACTIC SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY STEREOTACTIC SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ASTROCYTOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ASTROCYTOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ASTROCYTOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY GLIOBLASTOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY GLIOBLASTOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY GLIOBLASTOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY MENINGIOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY MENINGIOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY MENINGIOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. ASEAN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2032 (USD MILLION)
  • TABLE 193. ASEAN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 194. ASEAN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 195. ASEAN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 196. ASEAN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 197. ASEAN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. ASEAN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 199. ASEAN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 200. GCC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 201. GCC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. GCC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 203. GCC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2032 (USD MILLION)
  • TABLE 204. GCC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 205. GCC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 206. GCC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 207. GCC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 208. GCC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. GCC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 210. GCC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPEAN UNION BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPEAN UNION BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPEAN UNION BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPEAN UNION BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPEAN UNION BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPEAN UNION BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPEAN UNION BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPEAN UNION BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPEAN UNION BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. BRICS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. BRICS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 225. BRICS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2032 (USD MILLION)
  • TABLE 226. BRICS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 227. BRICS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 228. BRICS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 229. BRICS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 230. BRICS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. BRICS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 232. BRICS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 233. G7 BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 234. G7 BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. G7 BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 236. G7 BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2032 (USD MILLION)
  • TABLE 237. G7 BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 238. G7 BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 239. G7 BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 240. G7 BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 241. G7 BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. G7 BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 243. G7 BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 244. NATO BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 245. NATO BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 246. NATO BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 247. NATO BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2032 (USD MILLION)
  • TABLE 248. NATO BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 249. NATO BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 250. NATO BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 251. NATO BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 252. NATO BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 253. NATO BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 254. NATO BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 255. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 256. UNITED STATES BRAIN TUMOR THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 257. UNITED STATES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 258. UNITED STATES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 259. UNITED STATES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2032 (USD MILLION)
  • TABLE 260. UNITED STATES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 261. UNITED STATES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 262. UNITED STATES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 263. UNITED STATES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 264. UNITED STATES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. UNITED STATES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 266. UNITED STATES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 267. CHINA BRAIN TUMOR THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 268. CHINA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 269. CHINA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 270. CHINA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2032 (USD MILLION)
  • TABLE 271. CHINA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 272. CHINA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 273. CHINA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 274. CHINA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 275. CHINA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 276. CHINA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 277. CHINA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)